Conflict of Interest: This study was funded with an unconditional grant by AstraZeneca R&D, Mölndal, Sweden.
The Risk of Newly Diagnosed Asthma in Migraineurs With or Without Previous Triptan Prescriptions
Article first published online: 11 JAN 2008
© 2008 the Authors
Headache: The Journal of Head and Face Pain
Volume 48, Issue 4, pages 606–610, April 2008
How to Cite
Becker, C., Brobert, G. P., Almqvist, P. M., Johansson, S., Jick, S. S. and Meier, C. R. (2008), The Risk of Newly Diagnosed Asthma in Migraineurs With or Without Previous Triptan Prescriptions. Headache: The Journal of Head and Face Pain, 48: 606–610. doi: 10.1111/j.1526-4610.2007.01030.x
- Issue published online: 11 JAN 2008
- Article first published online: 11 JAN 2008
- Accepted for publication October 10, 2007.
- General Practice Research Database;
Background.— Previous observational studies reported an increased prevalence of asthma in migraine patients. Whether triptans affect the asthma risk has not yet been explored in an epidemiological study.
Objective.— To estimate the risk of newly diagnosed asthma in patients with a general practitioner-diagnosed migraine in the UK between 1994 and 2001.
Methods.— A population-based follow-up study and a nested case-control analysis were conducted using the General Practice Research Database.
Results.— The study encompassed 51,688 migraineurs and the same number of matched controls. In the follow-up analysis, the relative risk of developing asthma in migraineurs compared with non-migraineurs was 1.3 (95% confidence interval [CI] 1.1-1.4). In the nested case-control analysis, the adjusted odds ratio for asthma in migraineurs overall was 1.17 (95% CI 1.01-1.35), and for those with a recent triptan prescription 1.12 (95% CI 0.65-1.94).
Conclusion.— The risk of developing asthma was not materially altered for patients with a general practitioner-recorded migraine diagnosis, regardless of triptan use.